Effect of GM-CSF in combination with hepatitis B vaccine on revacination of healthy adult non-responders.

[1]  C. Mengoli,et al.  Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. , 2009, Vaccine.

[2]  L. Gavaldá,et al.  Timing of hepatitis B vaccination: its effect on vaccine response in health care workers. , 2007, Vaccine.

[3]  Araceli Hernández,et al.  Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. , 2007, Biologicals : journal of the International Association of Biological Standardization.

[4]  S. Husain,et al.  Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India. , 2005, World journal of gastroenterology.

[5]  J. Hildebrandt,et al.  Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man from in vitro results , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[6]  T. Jones,et al.  Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[7]  A. Floreani,et al.  Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. , 2004, Vaccine.

[8]  M. Hilleman.  Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. , 2003, Vaccine.

[9]  S. Lal,et al.  Immuneresponse to recombinant hepatitis B vaccination in adults. , 2003, The Journal of communicable diseases.

[10]  I. D. de Messias-Reason,et al.  Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. , 2003, Vaccine.

[11]  S. Reif,et al.  Decreased immune response to hepatitis B eight years after routine vaccination in Israel , 2003, Acta paediatrica.

[12]  F. Otaǧ.  False positive HBsAg result in blood donors due to administration of three different recombinant DNA Hepatitis B vaccines. , 2003, Vaccine.

[13]  H. van Loveren,et al.  Cytokine Polymorphisms Play a Role in Susceptibility to Ultraviolet B-Induced Modulation of Immune Responses after Hepatitis B Vaccination1 , 2003, The Journal of Immunology.

[14]  G. Drusano,et al.  Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. , 2003, Vaccine.

[15]  S. Agarwal,et al.  Efficacy of GM-CSF as an Adjuvant to Hepatitis B Vaccination in Patients with Chronic Renal Failure—Results of a Prospective, Randomized Trial , 2003, Renal failure.

[16]  H. van Loveren,et al.  IL-1beta gene polymorphisms influence hepatitis B vaccination. , 2002, Vaccine.

[17]  M. Yaron,et al.  Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis , 2002, Annals of the rheumatic diseases.

[18]  R. Idilman,et al.  The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C , 2002, American Journal of Gastroenterology.

[19]  L. Doğancı,et al.  Seroconversion rates of two different doses of hepatitis B vaccine in Turkish haemodialysis patients. , 2001, Central European journal of public health.

[20]  J. Holley,et al.  The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. , 2000, Clinical nephrology.

[21]  C. Tinelli,et al.  Early immunisation with hepatitis B vaccine: a five-year study. , 2000, Vaccine.

[22]  B. Bastani,et al.  Granulocyte-Macrophage Colony-Stimulating Factor as an Adjuvant to Hepatitis B Vaccination in Maintenance Hemodialysis Patients , 2000, American Journal of Nephrology.

[23]  U. Liebert,et al.  Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C , 2000, Hepatology.

[24]  J. Treanor,et al.  Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. , 1999, The Journal of infectious diseases.

[25]  S. Sarin,et al.  Granulocyte–macrophage colony‐stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients , 1999, Journal of viral hepatitis.

[26]  L. Hwang,et al.  Hepatitis B vaccination in high-risk infants: 10-year follow-up. , 1999, The Journal of infectious diseases.

[27]  H. Margolis,et al.  Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. , 1998, American journal of preventive medicine.

[28]  P. Goldwater.  Randomized, comparative trial of 20 μg vs 40 μg Engerix B vaccine in hepatitis B vaccine non-responders , 1997 .

[29]  M. Guillaume,et al.  Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. , 1996, Vaccine.

[30]  K. Deusch,et al.  The effect of granulocyte—macrophage colony‐stimulating factor (GM‐CSF) on hepatitis B vaccination in haemodialysis patients , 1996, Journal of viral hepatitis.

[31]  M. Kane.  Global programme for control of hepatitis B infection. , 1995, Vaccine.

[32]  P. Linsley,et al.  Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. , 1994, Journal of immunology.

[33]  A. Burgess,et al.  Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor , 1992 .

[34]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.

[35]  S. Meuer,et al.  Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure. , 1990, Kidney international.

[36]  M. Garovoy,et al.  Altered monocyte function in uremia. , 1990, Clinical immunology and immunopathology.

[37]  E. Engleman,et al.  Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. , 1990, The Journal of clinical investigation.

[38]  S. Meuer,et al.  Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. , 1987, The Journal of clinical investigation.

[39]  J. Lifter,et al.  T cell subsets and cellular immunity in end-stage renal disease. , 1983, The American journal of medicine.

[40]  W. Wilson,et al.  IMMUNOLOGIC STUDIES IN HUMAN ORGAN TRANSPLANTATION I. OBSERVATION AND CHARACTERIZATION OF SUPPRESSED CUTANEOUS REACTIVITY IN UREMIA , 1964 .

[41]  M. Prinzmetal,et al.  Studies on coronary circulation; quantitative changes in a serum mucoprotein following the occurrence of myocardial infarction. , 1949, The American journal of medicine.